Navigation Links
Heart Treatment from Vasogen Shows Promise

Researchers said that although the heart treatment from Canadian biotech firm Vasogen Inc. failed a key clinical trial hurdle in June, has still helped more than 70 per cent of patients.//

Vasogen chief executive officer David Elsley said that he was confident the detailed analysis presented at the World Congress of Cardiology meant its Celacade device-based therapy now had a promising commercial future.

According to Celacade if all goes well it could go on sale in Europe around the middle of 2007, although more clinical studies would be needed before it is launched in the United States.

In June when news that Celacade had not reached its primary goal of significantly reducing the overall risk of death and cardiovascular hospitalization in a 2,408-patient Phase III clinical trial shares in Vasogen fell more than 70 per cent.

However on review of the full data set released yesterday it was seen that there was a 21-per-cent reduction in risk in a 1,746 patient sub-group and they had not progressed to the more advanced stages of heart failure.

Researcher, Dr. James Young of the Cleveland Clinic Foundation said ,"The significant risk reduction observed on top of optimal heart failure therapy in over 70 per cent of study patients who were not in the more advanced stages of the condition -- and the consistency of the risk reduction across a number of different analyses -- are very compelling."

According to Mr. Elsley he was already in advanced discussions with a number of potential partners who could market Celacade, initially in Europe, where the treatment already has a CE mark, or regulatory approval.

He said, "Our therapy has been shown to be effective in patients that have not progressed to late-stage disease, at which point they become refractory to intervention. We are looking at a very broad population."

The recent review showed that Celacade helped patients with class II chronic hear t failure, according to the assessment by the New York Heart Association as well as the more ailing class III and IV patients, provided they had not suffered a previous heart attack.

The initial setback to the hopes for Celacade had led to loss of confidence in the company But Mr. Elsley said he believed Vasogen's fortunes had turned, adding that the group hoped to receive a cash injection under a future Celacade marketing deal.

He said, "We certainly expect the market will be impressed by this data."

The Celacade technology involves taking a blood sample from patients with heart disease and treating it to target the chronic inflammation associated with cardiovascular disease. It is then re-administered to the patient intramuscularly.


NLA
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: